Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > I am getting the impression
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Comment by FredTheVoiceon Feb 24, 2021 6:11pm
89 Views
Post# 32653757

RE:RE:RE:RE:RE:I am getting the impression

RE:RE:RE:RE:RE:I am getting the impressionAnalia,

Well, I understand your point of view, but still, I dont think you are evaluating properly what could happen with this stock within the next months......

Some companies in situation of bankrupcy went to visit the sky lately, and you really think a company well runned and with this kind of pipeline, and with all this exciting news coming, and with sales growing....

You really think this will be at 5$C .....and if lucky, 6$....

I dont buy that.

And, I am seeing this company having a 2021 year on the stock market that will bring lots of attention to the story. And we have that kind of start actually.........volume for the stock has doubled...

Lets see, I respect your point of view, but I dont buy it.

FTV.   
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities